Brain Metastases Pipeline: Driving Innovation with 40+ Leading Companies Advancing Next-Generation Therapies | DelveInsight

The brain metastases market is rapidly advancing and fueled by groundbreaking research and innovative therapies from companies such as HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, and ImmunoChem Therapeutics. These industry pioneers are transforming treatment strategies and redefining the future of Brain metastases, bringing new hope to patients worldwide.

DelveInsight's "Brain metastases Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Brain metastases market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Brain metastases drugs, the Brain metastases pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Brain Metastases Pipeline Report
• DelveInsight's Brain metastases Pipeline analysis depicts a robust space with 40+ active players working to develop 45+ pipeline drugs for Brain metastases treatment.
• The leading Brain metastases companies include HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation, and others are evaluating their lead assets to improve the Brain metastases treatment landscape.
• Key Brain metastases pipeline therapies in various stages of development include HBI-8000, ANG1005, Azeliragon, Nivolumab, MW151, Paxalisib, AZD3759, Icotinib, TY-9591, BMX-001, AMG 510, JBI-2174, QBS72S, Palbociclib, Keynatinib, HKI-272, Tucatinib, Almonertinib, ABM-168, and others.
• In March 2025, the FDA granted orphan drug designation to NERLYNX® (neratinib) for breast cancer patients with brain metastases. Neratinib is a tyrosine kinase inhibitor approved for extended adjuvant treatment of HER2-positive breast cancer after trastuzumab therapy.
• In September 2024, a study presented at the ESMO congress showed that women with HER2-positive breast cancer, regardless of brain metastases, can benefit from AstraZeneca and Daiichi Sankyo's Enhertu. In the DESTINY-Breast12 trial, 61.6% of patients with brain metastases were alive without disease progression at one year, and the central nervous system progression-free survival rate was 58.9%, whether the metastases were stable or growing. These results underscore Enhertu's effectiveness in treating HER2-positive breast cancer with brain involvement.

Request a sample and discover the recent breakthroughs happening in the Brain metastases pipeline landscape @ https://www.delveinsight.com/report-store/brain-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Brain Metastases Overview
Brain metastases represent the most common type of brain tumor and are a frequent complication in cancer patients, affecting approximately 10% to 26% of individuals who succumb to their disease. Although few cases of brain metastases are curable with conventional treatments, advancements in care have made long-term survival and symptom management achievable with minimal side effects. As survival rates improve, there is growing emphasis on preserving neuro-cognitive function and enhancing patients' quality of life.

In the U.S., brain metastases account for an estimated 98,000 to 170,000 new cases annually, making them the most prevalent intracranial tumors. Several factors have contributed to the rising incidence, including longer survival among patients with metastatic disease due to newer systemic therapies such as immunotherapy. Additionally, improved detection of small, asymptomatic brain metastases through advanced MRI techniques has led to more frequent diagnoses.

Find out more about Brain metastases medication @ https://www.delveinsight.com/report-store/brain-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Brain Metastases Treatment Analysis: Drug Profile
ANG1005 - Angiochem
ANG1005 is a groundbreaking, targeted taxane derivative and the first oncology candidate from Angiochem's platform designed to effectively cross the blood-brain barrier (BBB). It consists of a paclitaxel conjugated to Angiopep-2, enabling the drug to penetrate the brain by binding to LRP-1, a receptor highly expressed on the BBB and in various tumor cells. Once across the BBB, ANG1005 continues to target LRP-1 to enter cancer cells, including those found in malignant gliomas and brain metastases.

Clinical development includes a Phase II open-label study in patients with breast cancer brain metastases (NCT01480583), which showed promising antitumor activity. Follow-up Phase II trials have explored its use in recurrent high-grade glioma (NCT01967810) and recurrent brain metastases in breast cancer (NCT02048059). ANG1005 is currently undergoing Phase III evaluation.

Azeliragon - Cantex Pharmaceuticals
Azeliragon is an oral, once-daily small molecule that blocks the receptor for advanced glycation end products (RAGE), disrupting its interactions with ligands like HMGB1 and S100 proteins-key drivers of tumor growth, metastasis, and resistance. By inhibiting RAGE, azeliragon targets the tumor microenvironment to suppress cancer progression.

Originally developed by vTv Therapeutics for Alzheimer's disease, the drug was licensed by Cantex in 2021. Preclinical studies have demonstrated its potential in various cancers, including glioblastoma, pancreatic cancer, and brain metastases from breast and lung cancers, as well as in cancer-related cognitive decline. Azeliragon is currently being assessed in Phase I/II clinical trials for brain metastases.

Key Brain Metastases Therapies and Companies
• ANG1005: Angiochem
• Azeliragon: Cantex Pharmaceuticals, Inc.
• AZD3759: Alpha Biopharma Ltd.
• HBI-8000: HUYA Bioscience
• Paxalisib: Kazia Therapeutics
• TY-9591: TYK Medicines
• BMX-001: BioMimetix
• AMG 510: Amgen
• RRx-001: EpicentRx, Inc
• JBI-778: Jubilant Therapeutics
• SONALA-001: SonALAsense

Learn more about the novel and emerging Brain metastases pipeline therapies @ https://www.delveinsight.com/report-store/brain-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Brain Metastases Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Brain Metastases Pipeline Report
• Coverage: Global
• Key Brain metastases Companies: HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation, and others.
• Key Brain metastases Pipeline Therapies: HBI-8000, ANG1005, Azeliragon, Nivolumab, MW151, Paxalisib, AZD3759, Icotinib, TY-9591, BMX-001, AMG 510, JBI-2174, QBS72S, Palbociclib, Keynatinib, HKI-272, Tucatinib, Almonertinib, ABM-168, and others.

Dive deep into rich insights for drugs used for Brain metastases treatment; visit @ https://www.delveinsight.com/report-store/brain-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Brain metastases Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Brain metastases Pipeline Therapeutics
6. Brain metastases Pipeline: Late-Stage Products (Phase III)
7. Brain metastases Pipeline: Late-Stage Products (Phase III)
8. Brain metastases Pipeline: Mid-Stage Products (Phase II)
9. Brain metastases Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.